Genprex

Monthly Archives: May 2018

Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program

AUSTIN, Texas, May 31, 2018 /PRNewswire/ — Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with WIRB-Copernicus Group, Inc. (“WCG”), through which WCG will serve as the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) of record for new clinical trial sites that Genprex anticipates adding to participate in its …

Read More

Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell

AUSTIN, Texas, May 29, 2018 /PRNewswire/ — Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, announced today that its management team will ring the Nasdaq stock market closing bell on Thursday, May 31, 2018, in celebration of the Company’s recent IPO on Nasdaq….

Read More

Genprex To Present At Upcoming Investor And Industry Conferences

AUSTIN, Texas and CAMBRIDGE, Mass., May 23, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:

Event: 2018 BIO International Convention
Date: June 5, 2018
Time: 2:30 PM EDT
Location: Boston, MA
Presenter: Dr….

Read More

Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program

AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data management services to help accelerate the clinical development of Genprex’s lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC)….

Read More

Genprex Announces $10 Million Private Placement

AUSTIN, Texas, May 7, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase agreements with institutional investors in connection with a private placement of $10.0 million of shares of its common stock and warrants….

Read More

Genprex To Present At 2018 Disruptive Growth & Healthcare Conference

AUSTIN, Texas, May 7, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that Rodney Varner, Chairman and CEO, will present at the 2018 Disruptive Growth & Healthcare Conference to be held in New York City on May 8-9, 2018.

Read More